Browse Drug Recalls

32 FDA drug safety recalls.

FDA Drug Recall Enforcement Database

Browse 32 FDA drug recall enforcement actions. Each entry includes the product description, reason for recall, classification (Class I through III based on severity), recalling firm, and distribution details. Use the filters below to search by year, classification, state, or keyword.

Drug Safety Recalls

Browse 32 FDA drug recalls.

Clear
DateProductReasonClassFirm
Nov 24, 2025 Duloxetine Delayed-Release Capsules, USP, 60 mg, 1000-Capsule bottles, Rx Onl... CGMP Deviations; presence of N-nitroso-duloxetine impurity above the FDA recommended limit Class II Breckenridge Pharmaceutical, Inc.
Nov 24, 2025 Duloxetine Delayed-Release Capsules, USP, 60 mg, 1000-Capsule bottles, Rx Onl... CGMP Deviations; presence of N-nitroso-duloxetine impurity above the FDA recommended limit Class II Breckenridge Pharmaceutical, Inc.
Oct 9, 2025 Duloxetine Delayed-Release Capsules, USP, 60 mg, a.) 90-count bottle (NDC: 51... CGMP Deviations: N-nitroso-duloxetine impurity above the safety assessment limit of 12.5ppm. Class II Breckenridge Pharmaceutical, Inc.
Aug 8, 2025 Duloxetine Delayed-Release Capsules, USP, 30 mg, 1,000 Capsules per bottle, R... CGMP deviations: N-nitroso-duloxetine impurity above the proposed interim limit. Class II Breckenridge Pharmaceutical, Inc.
Jul 25, 2025 Duloxetine Delayed-Release Capsules, USP, 60 mg, 1,000 Capsules per bottle, R... CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit. Class II Breckenridge Pharmaceutical, Inc.
Jul 15, 2025 Duloxetine Delayed-Release Capsules, USP, 60mg, 1,000-count bottles, Rx Only,... CGMP Deviations: Presence of N-nitroso-duloxetine impurity above safety assessment limit Class II Breckenridge Pharmaceutical, Inc.
Jun 30, 2025 Duloxetine Delayed-Release Capsules, USP, 40mg, 30-count bottles, Rx Only, ... CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit Class II Breckenridge Pharmaceutical, Inc.
Apr 14, 2025 Duloxetine Delayed-Release Capsules USP, 30 mg, a.) 90-count bottles (NDC# 51... CGMP Deviations: Presence of Nitrosamine Drug Substance Related Impurity above the proposed inter... Class II Breckenridge Pharmaceutical, Inc
Apr 14, 2025 Duloxetine Delayed-Release Capsules USP, 60 mg, 1000-count bottles, Rx Only, ... CGMP Deviations: Presence of Nitrosamine Drug Substance Related Impurity above the proposed inter... Class II Breckenridge Pharmaceutical, Inc
Mar 26, 2025 Duloxetine Delayed-Release Capsules, USP, 30 mg, Rx Only, 1,000 Capsules per ... CGMP Deviations: presence of Nitrosamine Drug Substance Related Impurity (NDSRI), N-nitroso-dulox... Class II Breckenridge Pharmaceutical, Inc.
Feb 28, 2025 Duloxetine Delayed-Release Capsules, USP, 60mg, Rx Only, 1000-count bottles, ... CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit. Class II Breckenridge Pharmaceutical, Inc.
Feb 28, 2025 Duloxetine Delayed-Release Capsules, USP, 30mg, Rx Only, 1000-count bottles, ... CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit. Class II Breckenridge Pharmaceutical, Inc.
Feb 28, 2025 Duloxetine Delayed-Release Capsules, USP, 20mg, Rx Only, 500-count bottles, M... CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit. Class II Breckenridge Pharmaceutical, Inc.
Dec 6, 2024 Duloxetine Delayed-Release Capsules, USP, 60 mg, Rx Only, 90-count bottles (N... CGMP Deviations: presence of N-nitroso-duloxetine impurity above FDA recommended interim limit. Class II Breckenridge Pharmaceutical, Inc
Dec 6, 2024 Duloxetine Delayed-Release Capsules, USP, 30mg, Rx Only, 90-count bottles (ND... CGMP Deviations: presence of N-nitroso-duloxetine impurity above FDA recommended interim limit. Class II Breckenridge Pharmaceutical, Inc
Oct 10, 2024 Duloxetine Delayed-Release Capsules, USP, 20mg, Rx Only, 500-count bottles, M... CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit Class II Breckenridge Pharmaceutical, Inc
May 17, 2024 Duloxetine Delayed-Release Capsules, USP, 60mg, 90-count bottle, Rx Only, Mf... CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit Class II Breckenridge Pharmaceutical, Inc
Apr 29, 2024 Duloxetine Delayed-Release Capsules, USP, 20 mg, , 500-count bottles, Rx Only... CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit Class II Breckenridge Pharmaceutical, Inc
Apr 29, 2024 Duloxetine Delayed-Release Capsules, USP, 30mg, Rx Only, (a) 90-count bottles... CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit Class II Breckenridge Pharmaceutical, Inc
Apr 29, 2024 Duloxetine Delayed-Release Capsules, USP, 60 mg, 90-count bottles, Rx Only, M... CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit Class II Breckenridge Pharmaceutical, Inc
Mar 2, 2023 Clobazam Tablets, 20 mg, CIV, 100-count bottle, Rx only, Manufactured by Cent... CGMP Deviations: Potential risk of Cross Contamination Class II Breckenridge Pharmaceutical, Inc
Mar 2, 2023 Clobazam Tablets, 10 mg, CIV, 100-count bottle, Rx only, Manufactured by Cent... CGMP Deviations: Potential risk of Cross Contamination Class II Breckenridge Pharmaceutical, Inc
Mar 2, 2023 Alprazolam Tablets, USP, 2 mg, CIV, packaged in: a)100-count bottle (NDC 5199... CGMP Deviations: Potential risk of Cross Contamination Class II Breckenridge Pharmaceutical, Inc
Mar 2, 2023 Alprazolam Tablets, USP, 0.5mg, CIV, packaged in: a) 100-count bottle (NDC 51... CGMP Deviations: Potential risk of Cross Contamination Class II Breckenridge Pharmaceutical, Inc
Mar 2, 2023 Alprazolam Tablets, USP, 0.25mg, CIV, packaged in: a) 100-count bottle (NDC 5... CGMP Deviations: Potential risk of Cross Contamination Class II Breckenridge Pharmaceutical, Inc
Mar 2, 2023 Alprazolam Tablets, USP, 1 mg, CIV, packaged in: a) 100-count bottle (NDC 519... CGMP Deviations: Potential risk of Cross Contamination Class II Breckenridge Pharmaceutical, Inc
Mar 11, 2021 Omeprazole Delayed-Release Capsules, USP, 20 mg, 1000 count bottles, Rx Only,... Failed Impurities/Degradation Specifications: Out-of-Specification results obtained for unknown i... Class II Breckenridge Pharmaceutical, Inc
Feb 24, 2020 Zoledronic Acid Injection 5 mg/100 mL (0.05 mg/mL), Solution for Intravenous ... Failed Impurities/Degradation Specifications: Out-of-specification results obtained for impuritie... Class III Breckenridge Pharmaceutical, Inc
Jan 24, 2020 Solifenacin Succinate Tablets, 5mg, packaged in a) 30-count bottles (NDC 5199... CGMP Deviations: During manufacturing Solifenacin Succinate Tablets might convert to Solifenacin ... Class II Breckenridge Pharmaceutical, Inc
Jan 24, 2020 Solifenacin Succinate Tablets, 10 mg, packaged in a) 30-count bottles (NDC 51... CGMP Deviations: During manufacturing Solifenacin Succinate Tablets might convert to Solifenacin ... Class II Breckenridge Pharmaceutical, Inc
Nov 6, 2018 Megestrol Acetate Oral Suspension, USP 625 mg/5mL, 150 mL bottle, Rx only, Di... Failed Stability Specifications: Out-of-Specification results obtained for particle size distribu... Class III Breckenridge Pharmaceutical, Inc.
Oct 21, 2015 Duloxetine Delayed-release Capsules, USP, 60 mg, Rx Only, 1000 count bottle, ... Presence of Foreign Tablets/Capsules: one foreign capsule identified as omeprazole 10 mg was foun... Class III Breckenridge Pharmaceutical, Inc

Frequently Asked Questions

When a drug safety issue is identified — through FDA inspections, laboratory testing, adverse event reports, or manufacturer quality checks — the responsible company issues a recall to remove the affected products from the market. Pharmacies pull the product from shelves, and consumers are advised to contact their healthcare provider for alternatives.

The leading causes include cGMP deviations, impurity contamination (including nitrosamines like NDMA), failed dissolution or stability testing, sterility issues, potency problems, labeling errors, and foreign particle contamination.

Use the search and filter tools on this page to look up specific medications, active ingredients, or manufacturers. Each recall entry includes the product description, lot numbers, and distribution details.